Legend Biotech's in vivo CAR-T therapy shows groundbreaking early success

Legend Biotech has unveiled promising early results for LB2501, its experimental in vivo CAR-T cell therapy. The treatment targets patients with relapsed or refractory B-cell non-Hodgkin lymphoma. This marks a significant step in the company’s mission to transform cancer care through advanced cell therapies. The company announced first clinical proof-of-concept data for LB2501 at a recent medical conference. In a Phase 1 study, a single infusion of the therapy produced dose-dependent CAR-T cell expansion without the need for lymphodepletion. At the higher dose level, LB2501 achieved a 100% objective response rate and an 83.3% complete response rate in patients with the disease.

Safety data were equally encouraging. No dose-limiting toxicities, serious adverse events, neurotoxicity, or deaths were reported. LB2501 is designed to generate CAR-T cells directly inside the patient after a single intravenous dose, targeting both CD19 and CD20 proteins.

B-cell non-Hodgkin lymphoma accounts for about 85% of all non-Hodgkin lymphoma cases. Legend Biotech, already a leader in CAR-T therapy with its approved product CARVYKTI for multiple myeloma, continues to expand its pipeline. The ongoing Phase 1 trial will further evaluate the therapy’s safety, tolerability, and efficacy in relapsed or refractory B-cell malignancies. The early success of LB2501 strengthens Legend Biotech’s position as a pioneer in cell therapy. The treatment’s high response rates and favourable safety profile suggest potential for future cancer care. The company plans to push forward with further innovation across its pipeline.